Correction for Hess et al., Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies

APPLIED BIOLOGICAL SCIENCES Correction for “Glycosylation profiles determine extravasation and disease-targeting properties of armed antibodies,” by Dario Venetz, Christian Hess, Chia-wei Lin, Markus Aebi, and Dario Neri, which appeared in issue 7, February 17, 2015, of Proc Natl Acad Sci USA (112:2000–2005; first published February 2, 2015; 10.1073/pnas.1416694112).
The authors note that Fig. 2 appeared incorrectly. The corrected figure and its legend appear below.
In vivo biodistribution profiles, microscopic analysis, and pharmacokinetic data. (A) Quantitative biodistribution profiles 24 h after i.v. administration to F9-tumor–bearing mice. TGE (blue), SE (red), desialylated TGE (DS; gray), and deglycosylated SE (DG; black) derived F8-IL9 products are shown. (B) Jux-taposition of immunofluorescence detection images of F8-IL9 at 24 h after i.v. administration or after ex vivo application onto F9 tumor sections. (Scale bar: 100 μm.) (C) Pharmacokinetic data of F8-IL9 from SE (red) and TGE (blue) during the first 6 h after injection.